International Journal of Hematology

DOI: 10.1007/s12185-019-02620-2 Pages: 1-8

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

1. The University of Texas MD Anderson Cancer Center, Department of Leukemia

2. University of California, Irvine, Chao Family Comprehensive Cancer Center

Correspondence to:
Jorge E. Cortes
Tel: +1-713-794-5783



Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) have near-normal life expectancies. With this comes the possibility of developing second cancers; we aimed to evaluate the incidence of second malignancies in patients with CML using Surveillance, Epidemiology, and End Results Program data. We identified 13,276 patients with CML newly diagnosed in 2001–2014. Patients who had prior history of cancer, a concurrent diagnosis of other malignancies in the same diagnostic year, or a second leukemia after CML diagnosis were excluded. Second malignancies were observed in 597 patients (4%) with a median follow-up of 69 months. The 5- and 10-year cumulative incidences of death for all patients were 30.5% and 41.8%. The 5- and 10-year cumulative incidences of second malignancies were 4.4% and 7.2%, respectively. The overall standardized incidence ratio (SIR) was 1.204. Increased SIRs compared to the general population were observed for the male genital system, 1.593; digestive system, 1.291; skin, 1.588; and urinary system, 1.366. Overall excess absolute risk was 1.714 per 1000 person-years at risk. Our results suggest that relative incidence of overall second malignancies in CML is slightly higher than that of the general population, with minimal increase in the excess absolute risk.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge